Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors

Nanotheranostics

article

Shuguftha Naz¹  Tuhina Banerjee¹  Filbert Totsingan²  Kalee Woody¹  Richard A. Gross²  Santimukul Santra¹ 

[1] Department of Chemistry, Pittsburg State University;Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute

关键词: lactonic sophorolipid;    HDAC inhibition;    ganetespib;    antioxidant nanoceria;    cancer therapy;   

DOI  :  10.7150/ntno.57675

学科分类：大气科学

来源: Ivyspring International Publisher

【 摘 要 】

Purpose: Non-Small-Cell Lung Cancer (NSCLC) has gained resistance to common chemo- and radiotherapy due to the oncogenic K-RAS mutations. In this work, lactonic sophorolipids (LSL), a constituent of natural sophorolipids known to inhibit histone deacetylase (HDAC) activity, is used to evaluate its potential anticancer property for the treatment of NSCLC. In addition, ganetespib (GT), a Hsp90 inhibitor, is used for its known antitumor activity in several K-RAS mutant NSCLC cells. We propose, a functional anti-oxidant nanomedicine composed of nanoceria (NC) encapsulated with two-drug cocktail LSL and GT for the assessment of therapeutic efficacy of LSL and targeted combination therapy of NSCLC. NC is an excellent redox platform specifically used to supplement the therapeutic potency of these drugs to target both HDAC inhibition and Hsp90 signaling pathways in NSCLC.

【 授权许可】

CC BY-NC